Is Calidi Biotherapeutics Stock a good buy in 2024, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NYSEMKT: CLDI) stock is to Buy CLDI stock.
Out of 2 analysts, 0 (0%) are recommending CLDI as a Strong Buy, 2 (100%) are recommending CLDI as a Buy, 0 (0%) are recommending CLDI as a Hold, 0 (0%) are recommending CLDI as a Sell, and 0 (0%) are recommending CLDI as a Strong Sell.
According to 2 Wall Street analysts that have issued a 1 year CLDI price target, the average CLDI price target is $3.25, with the highest CLDI stock price forecast at $4.50 and the lowest CLDI stock price forecast at $2.00.
On average, Wall Street analysts predict that Calidi Biotherapeutics's share price could reach $3.25 by Mar 21, 2025. The average Calidi Biotherapeutics stock price prediction forecasts a potential upside of 1,918.63% from the current CLDI share price of $0.16.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.